Azienda Ospedaliera Ordine Mauriziano Di Torino
Verified site
Turin, Italy
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The trial focuses on patients whose cancer has returned after initial chemotherapy and is still responsive to platinum‑based drugs. The cancers involved are a type of ovarian cancer called high‑grade serous ovarian cancer, as well as related cancers of the lining of the abdomen (primary peritoneal cancer) and the fallopian tubes. The investigational medicine is Raludotatug Deruxtecan, given through an intravenous infusion, and it may be combined with the antibody drug Bevacizumab. The purpose of the study is to determine whether this combination can keep the disease from progressing for a longer time than the usual standard treatment.
Participants who meet the study criteria will be assigned by chance to receive either the new drug alone, the new drug plus the antibody, or the current standard therapy. The assigned treatment is given by a drip into a vein every few weeks as a maintenance therapy, meaning it is used after the initial chemotherapy to try to prevent the cancer from coming back. The trial follows each participant for several months, with regular visits for safety checks, blood tests, and imaging scans to watch for any signs of disease growth. The study is open‑label, so the doctors and participants know which treatment is being given, and the overall design is a phase 3 trial, which is the final stage before a drug may be approved for general use.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
13 criteria
28 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an experimental medicine being tested in this study. It is given by an intravenous (IV) infusion, which means it is slowly dripped into a vein through a tube. In the trial, patients receive this drug after their cancer has responded to initial chemotherapy. The purpose of Raludotatug Deruxtecan is to try to keep the cancer from coming back and to extend the time patients live without their disease getting worse.
is a well‑known antibody that blocks a protein called VEGF, which tumors use to grow new blood vessels. In this study, some participants receive bevacizumab together with Raludotatug Deruxtecan, while others receive Raludotatug Deruxtecan alone. It is also given by IV infusion. The goal of adding bevacizumab is to see whether blocking blood‑vessel growth can improve the ability of the experimental drug to keep the cancer under control.
This medication is given as a solution for intravenous infusion. It is an investigational antibody‑drug conjugate that is still being studied in clinical trials and is not yet approved for general use. It is being tested as a maintenance treatment for platinum‑sensitive recurrent high‑grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer. It works by attaching a chemotherapy drug to an antibody that seeks out cancer cells, delivering the toxic payload directly to the tumor, and it is classified as an antibody‑drug conjugate (ADC).
This medication is also administered as a solution for intravenous infusion. It is an approved monoclonal antibody that has been widely used in many cancers, including ovarian cancer, and is listed in medical literature as a standard therapy. It blocks a protein called VEGF, which stops new blood vessels from forming and therefore slows tumor growth. It belongs to the class of VEGF inhibitors, a type of anti‑angiogenic therapy.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.